Loading
STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.
Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate.
CIViC holds 6 clinical evidence items and 0 assertions across 3 variants, naming Vemurafenib. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.00, somatic mutation 0.97). IntOGen calls it a driver in 19 cohorts (0 activating, 19 loss-of-function), covering Acute Myeloid Leukaemia, Bladder Urothelial Carcinoma, Renal Clear Cell Carcinoma, Ewing Sarcoma, Glioblastoma Multiforme, Lung Squamous Cell Carcinoma and others.
In plain words · STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.
STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.
Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped.
No product in this corpus aims at STAG2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA STAG2: RNA low tissue specificity; high antibody staining in 13 normal tissues; highest cancer staining carcinoid (1 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Sarcomas (soft tissue, bone, GIST), Renal cell carcinoma, Endometrial cancer, Thyroid cancer, Breast cancer (all types), Leukaemia and more); Open Targets associates it with 2 specific cancer types at or above 0.5 (urinary bladder cancer, Ewing sarcoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q8N3U4; CIViC gene STAG2; IntOGen STAG2; Human Protein Atlas STAG2 tissue; Open Targets ENSG00000101972 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Carramolino et al, Gene, 1997, "SA-1, a nuclear protein encoded by one member of a novel gene family: molecular cloning and detection in hemopoietic organs". Source.
Sources: HGNC HGNC:11355 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8N3U4 (protein name, function text, keywords and locations (REST API)); CIViC gene STAG2 (6 evidence items, 0 assertions, 3 variants; diseases: Acute Myeloid Leukaemia, Melanoma, Bladder Carcinoma, Ewing Sarcoma Of Bone, Bladder Urothelial Papillary Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000101972 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: urinary bladder cancer 0.66, endometrial cancer 0.52, sarcoma 0.62, skin cancer 0.51, myeloproliferative neoplasm 0.53, Ewing sarcoma 0.52 (GraphQL API, CC0)); IntOGen STAG2 (driver in 19 cohorts (Act 0, LoF 19); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The cohesin complex may also play a role in spindle pole assembly during mitosis. Location: Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus Xq25 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex, Cervix.
Medium only: cervical cancer, endometrial cancer, glioma, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"STAG2" OR ABSTRACT:"STAG2" OR TITLE:"STAG2 cohesin complex component" OR ABSTRACT:"STAG2 cohesin complex component" OR TITLE:"Cohesin subunit SA-2" OR ABSTRACT:"Cohesin subunit SA-2" OR TITLE:"SA-2" OR ABSTRACT:"SA-2" OR TITLE:"SCC3B" OR ABSTRACT:"SCC3B" OR TITLE:"SA2" OR ABSTRACT:"SA2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAG2, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Sarcomas (soft tissue, bone, GIST), Bladder & urothelial cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Renal cell carcinoma, Bladder & urothelial cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, Sarcomas (soft tissue, bone, GIST).
Shares Leukaemia (all types), Endometrial cancer, Sarcomas (soft tissue, bone, GIST), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Bladder & urothelial cancer, CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Thyroid cancer, Leukaemia (all types), IntOGen.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, Bladder & urothelial cancer.